JP2006521399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521399A5 JP2006521399A5 JP2006509357A JP2006509357A JP2006521399A5 JP 2006521399 A5 JP2006521399 A5 JP 2006521399A5 JP 2006509357 A JP2006509357 A JP 2006509357A JP 2006509357 A JP2006509357 A JP 2006509357A JP 2006521399 A5 JP2006521399 A5 JP 2006521399A5
- Authority
- JP
- Japan
- Prior art keywords
- neuropathic pain
- compound
- receptor subtype
- selectively activates
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004296 neuralgia Diseases 0.000 claims 13
- 208000021722 neuropathic pain Diseases 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000018380 Chemical injury Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 238000002266 amputation Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45904503P | 2003-03-28 | 2003-03-28 | |
| PCT/US2004/009339 WO2004087158A2 (en) | 2003-03-28 | 2004-03-26 | Muscarinic m1 receptor agonists for pain management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006521399A JP2006521399A (ja) | 2006-09-21 |
| JP2006521399A5 true JP2006521399A5 (cg-RX-API-DMAC7.html) | 2007-05-10 |
Family
ID=33131858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509357A Withdrawn JP2006521399A (ja) | 2003-03-28 | 2004-03-26 | 疼痛管理用ムスカリンｍ１受容体アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050130961A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1613321A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006521399A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050112116A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1777425A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004226430A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0409523A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2520125A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05010171A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ542690A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2358735C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004087158A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200508733B (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| AU2002359875B2 (en) * | 2001-12-28 | 2009-01-08 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| US20080015225A1 (en) * | 2004-07-16 | 2008-01-17 | Janssen Pharmaceutica N.V. | Dimeric Piperidine Derivatives |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010504359A (ja) | 2006-09-20 | 2010-02-12 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法 |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CA2712731C (en) | 2008-01-22 | 2016-05-03 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| MX2012010470A (es) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5). |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| JP2016513677A (ja) * | 2013-03-15 | 2016-05-16 | アカディア ファーマシューティカルズ インコーポレイテッド | ムスカリンアゴニスト |
| ES2811088T3 (es) | 2014-04-23 | 2021-03-10 | Takeda Pharmaceuticals Co | Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer |
| EP3313836B1 (en) | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| JP2022523355A (ja) * | 2019-02-22 | 2022-04-22 | カルナ セラピューティックス，インコーポレイテッド | 神経障害の処置のための重水素化キサノメリンの化合物及び方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8717446D0 (en) * | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5155166A (en) * | 1990-06-18 | 1992-10-13 | Eastman Kodak Company | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same |
| FR2663929A1 (fr) * | 1990-06-29 | 1992-01-03 | Adir | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| GB2292685A (en) * | 1994-07-27 | 1996-03-06 | Sankyo Co | Allosteric effectors at muscarinic receptors |
| US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| WO2000030632A1 (en) * | 1998-11-23 | 2000-06-02 | Eisai Co., Ltd. | Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists |
| TWI310035B (en) * | 2000-04-28 | 2009-05-21 | Acadia Pharm Inc | Muscarinic agonists |
| RU2288919C2 (ru) * | 2001-10-02 | 2006-12-10 | Акадиа Фармасьютикалз, Инк. | Производные бензимидазолидинона в качестве агентов мускариновых рецепторов |
| AU2002359875B2 (en) * | 2001-12-28 | 2009-01-08 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
-
2004
- 2004-03-26 CN CNA2004800104664A patent/CN1777425A/zh active Pending
- 2004-03-26 WO PCT/US2004/009339 patent/WO2004087158A2/en not_active Ceased
- 2004-03-26 MX MXPA05010171A patent/MXPA05010171A/es unknown
- 2004-03-26 RU RU2005133197/14A patent/RU2358735C2/ru active
- 2004-03-26 KR KR1020057018253A patent/KR20050112116A/ko not_active Ceased
- 2004-03-26 JP JP2006509357A patent/JP2006521399A/ja not_active Withdrawn
- 2004-03-26 EP EP04758412A patent/EP1613321A2/en not_active Withdrawn
- 2004-03-26 AU AU2004226430A patent/AU2004226430A1/en not_active Abandoned
- 2004-03-26 US US10/809,975 patent/US20050130961A1/en not_active Abandoned
- 2004-03-26 NZ NZ542690A patent/NZ542690A/en unknown
- 2004-03-26 BR BRPI0409523-5A patent/BRPI0409523A/pt not_active IP Right Cessation
- 2004-03-26 CA CA002520125A patent/CA2520125A1/en not_active Abandoned
-
2005
- 2005-10-27 ZA ZA200508733A patent/ZA200508733B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007145875A5 (cg-RX-API-DMAC7.html) | ||
| JP2011528713A5 (cg-RX-API-DMAC7.html) | ||
| JP2021063088A5 (cg-RX-API-DMAC7.html) | ||
| JP2009511595A5 (cg-RX-API-DMAC7.html) | ||
| JP2009514835A5 (cg-RX-API-DMAC7.html) | ||
| RU2005133197A (ru) | Агонисты м1 мускариновых рецепторов для противоболевой терапии | |
| JP2010522242A5 (cg-RX-API-DMAC7.html) | ||
| JP2008524331A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516371A5 (cg-RX-API-DMAC7.html) | ||
| JP2009514836A5 (cg-RX-API-DMAC7.html) | ||
| JP2007537301A5 (cg-RX-API-DMAC7.html) | ||
| JP2012509348A5 (cg-RX-API-DMAC7.html) | ||
| JP2010515715A5 (cg-RX-API-DMAC7.html) | ||
| JP2009501177A5 (cg-RX-API-DMAC7.html) | ||
| JP2009501178A5 (cg-RX-API-DMAC7.html) | ||
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| JP2008523153A5 (cg-RX-API-DMAC7.html) | ||
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| JP2011505356A5 (cg-RX-API-DMAC7.html) | ||
| RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника | |
| JP2021521118A5 (cg-RX-API-DMAC7.html) | ||
| JP2013506674A5 (cg-RX-API-DMAC7.html) | ||
| RU2019111421A (ru) | Способы лечения острого повреждения почек | |
| JP2008517059A5 (cg-RX-API-DMAC7.html) |